Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 2/20 | 0.34 |
| ▸ | SKP1 | P63208 | 2/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798838 | 0.91 | ADORA1 (0.35) | DRD2SIGMAR1IDO1CKS1BSKP1 | |
| SCHEMBL6791964 | 0.87 | KDM4E (0.35) | DRD2SIGMAR1CKS1BSKP1SKP2 | |
| SCHEMBL6794800 | 0.78 | DRD2 (0.35) | DRD2SIGMAR1IDO1CKS1BSKP1 | |
| SCHEMBL6794681 | 0.77 | DRD2 (0.38) | DRD2SIGMAR1CKS1BSKP1SKP2 | |
| SCHEMBL6790820 | 0.77 | CCNA2 (0.36) | DRD2SIGMAR1 | |
| SCHEMBL6793102 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL6792392 | 0.71 | CYP11B1 (0.39) | DRD2CKS1BSKP1SKP2NAMPT | |
| SCHEMBL6792969 | 0.70 | ADORA3 (0.35) | DRD2IDO1CKS1BSKP1SKP2 | |
| SCHEMBL20141718 | 0.70 | CKS1B (0.45) | DRD2SIGMAR1IDO1CKS1BSKP1 | |
| SCHEMBL6798834 | 0.69 | DRD2 (0.36) | DRD2SIGMAR1IDO1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DRD2 4396/4885SIGMAR1 4084/4885IDO1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.